Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Biocommodity refinery (BIOCORE)

Framework: FP7 — Cooperation
Programme: Food, Agriculture and Fisheries, and Biotechnology
Destination: Life sciences, biotechnology and biochemistry for sustainable non-food products and processes
Action type: Collaborative project
Countries involved: France,Finland,Netherlands,France,Greece,Germany,Belgium,France,Czechia,Netherlands,Sweden,Latvia,India,Germany,Netherlands,United Kingdom,France,Hungary,Netherlands,France,Belgium,Luxembourg
Call:  (FP7-2009-BIOREFINERY_CP, 2009)
Start date: 2010-03-01
End date: 2014-02-28
Duration (months): 48.0
Total project cost (EUR): 20522739.6
EU funding (EUR): 13920237.0
Participants: 26
Project status: CLOSED

BIOCORE will create and demonstrate create a lignocellulosic biorefinery for sustainable processing of agricultural residues (wheat and rice straws), SRC wood (poplar) and hardwood forestry residues, into 2G biofuels, bulk chemicals, polymers, speciality molecules, heat and power. To reach this overall objective, BIOCORE will: 1) Describe how a mixed lignocellulosic feedstock-based biorefinery can be supplied with biomass, taking into account biomass handling, feedstock variability and seasonality. Biomass provisioning scenarios will be described for several different local contexts (Europe and Asia) 2) Adapt and streamline a patented organosolv technology for targeted biorefining of BIOCORE feedstocks and develop all necessary processing steps (including enzymatic hydrolysis and physico-chemical operations) to produce high quality cellulose, polymeric and oligomeric hemicellulose-derivatives, high quality lignins, heat and power from process residues 3) Develop multiple product manufacturing pipelines using a combination of advanced biotechnologies, chemical catalysis and thermochemical processes for the production of building block chemicals and polymers for bulk markets from sugars and lignins 4) Design a complete biorefinery concept that will describe the alternative product manufacturing pathways. This will be achieved by developing integrated flowsheets and process designs that include all of the operational units, supply chain models, and economic factors 5) Demonstrate the performance of the biorefinery through an integrated approach, producing industrial scale pilots for the biorefinery complexes that are closer to the market 6) Assess the environmental, economic and social sustainability of the biorefinery concept considering the entire value chain 7) Ensure efficient technology transfer to the energy sector, chemical and biotech industries, agro and forestry sectors, and the general public and policy makers

Keywords: lignocellulosic feedstocks,non-food,multi-product biorefinery,organosolv,biotechnology,(thermo)chemical catalysis,olefins,building blocks,bulk polymers,commodity chemicals,bioethanol
European Obesity Consortium studying the Hypothalamus and its Interaction with Peripheral organs. (EUROCHIP)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,United Kingdom,France,Germany,Germany,Sweden,Germany
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2009-10-01
End date: 2013-09-30
Duration (months): 48.0
Total project cost (EUR): 3854510.04
EU funding (EUR): 2999996.0
Participants: 9
Project status: CLOSED

The past decade has seen tremendous progress in our understanding of homeostatic regulators controlling energy balance. Insights from human and murine genetics have illuminated multiples pathways within the hypothalamus, brainstem and higher brain regions that play a key role in the control of food intake, whilst physiological studies focusing on the gastrointestinal tract have revealed a panoply of hormones that are secreted in response to or in anticipation of food intake and act centrally to regulate appetite. EurOCHIP brings together world leaders specializing in both areas in order to explore the interaction between the periphery and the brain in the control of energy homeostasis. Our programme of research will comprise four interdependent work-packages: i) characterising the interaction of gastrointestinal hormones with the hypothalamus and brainstem, with the aim of identifying novel molecules and pathways that mediate food intake; ii) using imaging techniques and behavioural phenotyping to explore the response of brain areas involved in higher cognitive and affective functions to these gastrointestinal hormones; iii) harnessing the power of human genetics to determine the role of sequence variation in and around newly identified candidate genes in appetitive behaviour and response to dietary interventions, focusing in particular on childhood obesity and iv) determining the effects of specific dietary interventions on gastrointestinal hormone secretion and using pharmacological studies in humans to mimic the hormonal milieu seen after a meal or bariatric surgery.

Keywords: obesity,hypothalamus,brainstem,gut peptides,hormones,genetics,endocrine,reward,appetite
Sea Border Surveillance (SEABILLA)

Framework: FP7 — Cooperation
Programme: Security
Destination: Intelligent surveillance and enhancing border security
Action type: Collaborative project
Countries involved: Italy,United Kingdom,France,Portugal,Spain,Sweden,Spain,European organisations area,France,France,Belgium,Germany,Netherlands,Italy,Spain,Spain,United Kingdom,France,Israel,Netherlands
Call:  (FP7-SEC-2009-1, 2009)
Start date: 2010-06-01
End date: 2014-02-28
Duration (months): 45.0
Total project cost (EUR): 15558125.8
EU funding (EUR): 9841603.55
Participants: 28
Project status: CLOSED

The SeaBILLA proposal aims to 1) define the architecture for cost-effective European Sea Border Surveillance systems, integrating space, land, sea and air assets, including legacy systems; 2) apply advanced technological solutions to increase performances of surveillance functions; 3) develop and demonstrate significant improvements in detection, tracking, identification and automated behaviour analysis of all vessels, including hard to detect vessels, in open waters as well as close to coast. SeaBILLA is based on requirements for Sea Border Surveillance defined by experienced operational users. These requirements have been transformed into Scenarios, included in Annex to this proposal, representative of gaps and opportunities for fruitful cooperative information exchange between Members States a) for fighting drug trafficking in the English Channel; b) for addressing illegal immigration in the South Mediterranean; c) for struggling illicit activities in open-sea in the Atlantic waters from Canary Islands to the Azores; in coherence with the EU Integrated Maritime Policy, EUROSUR and Integrated Border Management, and in compliance with Member States sovereign prerogatives. The project will provide concrete added value and benefits for users, by providing a solution that can be implemented at national and EU level to increase effectiveness, pool resources and address Maritime Security and Safety challenges; for world competitiveness of EU industries, by increasing knowledge and reducing risks for future product investments; for European citizens, by providing effectively deployable solutions for law enforcement along the European sea borders. SeaBILLA will be carried out by a reliable team of major European system integrators, technology providers and leading research organizations, establishing strong links with several EU and national projects and assuring worldwide exploitation of project results.

Keywords: integrated sea border surveillance,maritime security,data fusion,user driven project.,operamar,eurosur,non conventional sensors improvements,imagery chain management,vessel behaviour analysis
Sustainable products from economic processing of biomass in highly integrated biorefineries (SUPRA-BIO)

Framework: FP7 — Cooperation
Programme: Energy
Destination: Renewable fuel production
Action type: Collaborative project
Countries involved: United Kingdom,Norway,Netherlands,Germany,Germany,Denmark,Germany,France,United Kingdom,Germany,Denmark,Sweden,Switzerland
Call:  (FP7-2009-BIOREFINERY_CP, 2009)
Start date: 2010-02-01
End date: 2014-07-31
Duration (months): 54.0
Total project cost (EUR): 17460611.67
EU funding (EUR): 12318163.0
Participants: 20
Project status: CLOSED

Economic and sustainable production of fuels, chemicals and materials from biomass requires capture of the maximum energy and monetary value from sustainable feedstock. SUPRA-BIO achieves this by focussing on innovative research and development of critical unit operations, by using process intensification to match economic production to the scale of available feedstock and by process integration that provides energy from process waste, optimises utilities to minimise environmental impact and maximises value from the product mix. A technology toolbox for conversion and separation operations is developed that adapts to various scenarios of product mix and feedstock. These are contextualized by full life cycle and economic analysis of potential biorefinery schemes. Based on lignocellulose, microbial/organic waste or microalgae feedstock, innovation and intensification are used to improve the economics and carbon efficiency of fractionation, separation, bio and thermochemical conversions to produce biofuels, intermediates and high value products. Strain selection, genetic manipulation, molecular design and nanocatalysis are used to improve productivity and selectivity; reactor design, intensification and utilities integration for economics. Fermentation to 2,3 butanediol is demonstrated. Mono and multiculture processes are researched for high value products and feedstock streams. Separation is developed for omega oils and specific lignochemicals. Nano and biocatalytic processes are developed for biofuels and bioactive molecules. Integration into potential biorefinery schemes is explored in laboratory pilots of integrated reactors, by piloting on sidestreams, by exchanging separated fractions between partners and by process evaluations. The project includes all the scientific, engineering and industrial skills required to produce the step changes required for biorefineries to impact significantly on realising the aims of the European Strategic Energy Technology Plan

Keywords: sustainable,biomass,biorefinery,second generation fuels,nanomaterials lignochemicals,integration,life cycle analysis
Health Competence in Europe (HEALTHCOMPETENCE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: France,Germany,Belgium
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2009-10-01
End date: 2014-09-30
Duration (months): 60.0
Total project cost (EUR): 868885.93
EU funding (EUR): 800000.0
Participants: 4
Project status: CLOSED

The results generated through EC funded projects represent a considerable part of health research in Europe. Access to high-quality information on these research activities &amp; results is therefore critical for planning &amp; strategic decision making, and hence strengthening the involved stakeholders&apos; innovation capabilities. The objective of HealthCompetence is to ensure an adequate access to this information by implementing a web-based Monitoring Tool that makes key information on all FP6&amp;7 Health related projects, including thereto related competencies and results, accessible to its stakeholders (project coordinators, scientists, technology transfer officers, policy makers &amp; programme managers within academia, industry &amp; the European Commission). The Monitoring Tool serves to support the stakeholders in their efforts to find collaboration partners, do benchmarking, analyse networks and get answers to European policy issues. HealthCompetence will take the results of LifeCompetence, developed by one of the Consortium members, as a starting point for implementation. LifeCompetence has resulted in a popular web platform &quot;making research competencies accessible&quot;, based on projects funded by FP6 Life Science &amp; Health. HealthCompetence will broaden the content to make the competence profiles more complete and enable answers to tech transfer issues by integrating information on the projects’ results from public databases on publications, patents &amp; technology offers. The results will also be deepened to ensure a continuously reliable data quality. As satisfactory data quality for monitoring cannot be achieved only through automatic means, the project will also implement systematic and efficient validation processes combined with versatile possibilities to use and get value from the information. The project partners &amp; management structure integrate all key stakeholders to ensure the end results match their needs and the operation of the Monitoring Tool becomes sustainable.

Keywords: monitoring,technology transfer,commercialisation,research collaboration,evaluation,research performance assessment,research policy,strategic planning,research information management.
Development of a high sensitive and specific nanobiosensor based on surface enhanced vibrational spectroscopy dedicated to the in vitro proteins detection and disease diagnosis (NANOANTENNA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: France,Spain,Germany,Italy,Israel,Spain,Italy,France,France,Austria
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2009-10-01
End date: 2013-03-31
Duration (months): 42.0
Total project cost (EUR): 5920214.52
EU funding (EUR): 3999925.8
Participants: 12
Project status: CLOSED

The main goal of our proposal is to develop a novel optical nanobiosensor based on extraordinary vibrational signal enhancement of the proteins to be detected. To reach vibrational signal enhancement, we will exploit the optical properties of specially designed metallic nanoparticles which should act as nanoantenna and the associated field enhancement to obtain a direct detection of proteins bound to the nanoparticle. Thus, our sensor will reach high sensitivity provided by the recently established large enhancement of vibration signals due to the resonant excitation of the nanoantenna device used as substrates. The aim is to detect only a few proteins with concentration much lower than 1pM and finally to reach detection threshold such as femtomole or lower. High molecular selectivity will be reached with the functionalisation of the nanoantenna. Such functionalisation will selectively favour the immobilisation of the protein to be detected at the vicinity of the nanoparticle surface, providing the best enhancement and then the detection of the targeted protein. Our nanobiosensor will include two main components: the nanoantenna device which corresponds to our sensor transducer and the functionalisation which corresponds to its bioreceptor. And then, each functionalised nanoantenna device used as vibrational signal enhanced system is an individual and specific nanosensor of proteins. As a consequence, our nanobiosensor integrated in a vibrational spectroscope will allow the detection and the analysis of the enhanced vibrational signal from the targeted proteins and thus corresponds to our diagnosis instrument. Our nanobiosensor will be validated on the detection of proteins on body fluids.These proteins have been chosen since they have been identified as specific biomarkers of common pathologies. This validation will be applied it to improve their detection (better sensitivity, decrease of the detection threshold) and open the way to the early diagnosis.

Keywords: nanobiosensor,diagnosis,proteins,protein detection,nanoantenna,optical properties,vibrational fingerprint
Blood-brain barrier junctions as targets for paracellular drug delivery to the brain (JUSTBRAIN)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Switzerland,Italy,Germany,France,Germany
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2009-11-01
End date: 2014-04-30
Duration (months): 54.0
Total project cost (EUR): 4062475.0
EU funding (EUR): 2989845.0
Participants: 7
Project status: CLOSED

To maintain homeostasis of the central nervous system (CNS) the blood-brain barrier (BBB) prevents the free transcellular passage of hydrophilic molecules from the blood into the CNS. Because of this, the BBB is now recognised as the major obstacle to the treatment of most neurological disorders, as it hinders the delivery of many potentially important therapeutic and diagnostic substances to the CNS. Previous approaches in improving drug delivery across the BBB, which have primarily aimed at highjacking the transcellular transport machinery that is dedicated to the selective transport of specific molecules across the BBB, have had limited success, especially with regard to large molecular weight drugs. Lack of knowledge on the molecular composition and function of cerebrovascular cell-to-cell junctions has hampered the development of safe strategies for paracellular drug delivery across the BBB until recently. Members of the JUSTBRAIN consortium have accumulated knowledge on the structure and function of BBB cell-to-cell junctions, identified endothelial signals controlling the expression of individual junctional proteins and have begun to develop approaches, which may either open or close BBB junctions. Using in vitro and in vivo BBB models and animal models of neurological disorders, where BBB opening may be therapeutic, JUSTBRAIN is dedicated to translate this basic knowledge into identifying an entire novel platform of drugable molecular targets that could be functionally modulated thus allowing to bypass the BBB via the paracellular route. By these means JUSTBRAIN expects to improve efficient delivery of large molecules into the CNS and thus to expand on diagnostic and therapeutic possibilities for neurological disorders.

Keywords: endothelial junctions,paracellular drug delivery,claudins blood-brain barrier,neurological disorders
Schistosoma Epigenetics - Targets, Regulation, New Drugs (SETTREND)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: France,France,Germany,Brazil,Germany,Sweden
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2012-12-31
Duration (months): 36.0
Total project cost (EUR): 4326503.0
EU funding (EUR): 3299998.0
Participants: 9
Project status: CLOSED

We propose to develop novel drug leads for the therapy of the major human parasitic disease, schistosomiasis, using a holistic approach that will enable us to progress from the cloned target protein to the lead compound and from epigenetic inhibitors to crucial targets. For this, we have chosen to target the histone modifying enzymes (HME); histone deacetylases (HDAC), histone acetyltransferases (HAT), histone methyltransferases (HMT) and histone demethylases (HDM) of Schistosoma mansoni. In the course of the project the members of HDAC classes I, II and III (sirtuins) HAT, HMT and HDM encoded in the genome will be identified. In parallel, a reverse chemical genetics approach using generic inhibitors of HME subclasses available within the consortium in cultures of schistosome larvae will identify those classes that are bona fide drug targets. These enzymes will be validated as therapeutic targets individually or collectively using RNAi to invalidate the corresponding genes. Potential inhibitors (HDACi, HATi, HMTi, HDMi) will be screened by in silico docking to the modelled catalytic domains of the enzymes and collections of analogues will be tested for their ability to inhibit the activity of the corresponding recombinant proteins in high-throughput assays. We will also establish gene expression profiles corresponding to HME invalidation (by RNAi) and inhibition (using drug candidates in cultured larval stages (schistosomula) that will enable the determination of the specificity of action of the drugs. Finally, in vivo testing of the best candidates will be done in infected mice. In this way, during the study period we aim to develop a series of candidate molecules that can progress to clinical trials.

Keywords: schistosoma,histone modifying enzyme,epigenetics,molecular modelling,high-throughput screen,inhibitor,rnai,gene expression signature,drug
European Consortium for Communicating Stem Cell Research (EUROSTEMCELL)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: United Kingdom,Italy,Belgium,United Kingdom,Germany,Spain,Sweden,Ireland,United Kingdom,France,United Kingdom
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-03-01
End date: 2015-02-28
Duration (months): 60.0
Total project cost (EUR): 848428.75
EU funding (EUR): 830238.0
Participants: 11
Project status: CLOSED

The European Consortium for Communicating Stem Cell Research, EUROSTEMCELL, brings together the major current FP6 and FP7 stem cell projects, the European Clinical Research Infrastructure Network, and four internationally recognized European stem cell centres to develop a comprehensive, coordinated platform for collation, dissemination and archiving of information on stem cell biology and regenerative medicine. Our aims are to address the urgent need for trusted, high quality information on stem cells by citizens and stakeholders across Europe, and further to establish a model for large-scale dissemination of Framework-funded research outputs to European publics. Dissemination of key advances will be achieved through a structured approach aimed at reaching European citizens and stakeholders at all educational levels. We will focus on three major dissemination routes: the worldwide web; resources for direct public engagement; and resources for educators. Emphasis will be placed on clear exposition of the potential applications and benefits for citizens of existing knowledge and new developments in stem cell research. To ensure continuous development of best practice, we will iteratively evaluate and refine all activities throughout the project. The project centrepiece will be a multi-lingual website, the European Stem Cell Information Portal www.eurostemcell.org, which we will create and develop as the premier European reference site for stem cell information and discourse. The consortium comprises the principal stem cell laboratories across Europe, including new member states, and additionally offers outstanding expertise in ethical and societal concerns and in evaluating clinical outcomes. This coalition provides unparalleled expertise across the field of stem cell biology and regenerative medicine, and is uniquely placed to achieve the vision of a trusted and accessible European stem cell information resource that promotes and facilitates public dialogue.

Keywords: outreach,dissemination,stem cells,stakeholders,museums,schools,press